Prostate cancer - Discussions


GETUG-AFU 18
ASCO GU 2024
Is "more" always better?


BRCAaway
ASCO GU 2024
BRCAAway - practice changing or hypothesis generating…


CONTACT-2
ASCO GU 2024
Cabo + IO: Interesting but not practice changing?!


EMBARK
ASCO GU 2024
Combination vs. monotherapy - a great new option for…
Prostate cancer - 100 sec


ASCO GU 2024
Salvage radiation with anti-androgen superior to…


ASCO GU 2024
Relugolix combined with androgen signaling in real word…


BCRAAway
ASCO GU 2024
Combination NHT + PARP makes sense


ASCO GU 2024
Gleason 3+3 - cancer or not?


ASCO GU 2024
Cognitive function in ART treatment


EMBARK, Prostate Cancer General Session
ASCO GU 2024
Dose de-escalation in different ways


EMBARK
ASCO GU 2024
Enzalutamide therapy as option for biochemical…


BRCAAway, CONTACT-02
ASCO GU 2024
Insights and news for mCRPC


CONTACT-2
ASCO GU 2024
Still a difficult time for androgenic inhibitors in…


CONTACT-2
ASCO GU 2024
What about the clinical benefit?


ASCO GU 2024
Therapy Intensification Still Neglected in mHSPC


CONTACT-2
ASCO GU 2024
First positive study of IO therapy in mCRPC


SEPTA
ASCO GU 2024
Stockholm3 validated in multiethnic cohort


EMBARK, GETUG-AFU
ASCO GU 2024
Localized PCa - news for radiotherapy and biochemical…


BCRAAway
ASCO GU 2024
Evaluating the recombination-repair mutations in…


CONTACT-2
ASCO GU 2024
Combination of cabozantinib & checkpoint inhibitor


BRCAaway
ASCO GU 2024
BRCAaway - PARP combination study


GETUG-AFU 18
ASCO GU 2024
Higher radiation is effective in high-risk PCA


FORMULA-509
ASCO GU 2024
Quality of life under intensive therapy


GETUG-AFU 18
ASCO GU 2024
Long-term dose escalation - Therapy in high-risk…


BRCAaway
ASCO GU 2024
Olaparib + Arbiraterone better compared to either alone


BCRAAway
ASCO GU 2024
Further testing before olaparib combination
Prostate cancer - multilanguage


BRCAaway
ASCO GU 2024
mCRPC de Olaparib+Abi , tek tek herbirinden ustun


CONTACT-2
ASCO GU 2024
Kombination av cabozantinib och immunterapi


CONTACT-2
ASCO GU 2024
Une période encore difficile pour les inhibiteurs…


CONTACT-2, BCRAAway
ASCO GU 2024
Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…


SEPTA
ASCO GU 2024
SEPTA calismasi: Stockholm3 un multietnik hasta…


Prostate Cancer General Session
ASCO GU 2024
PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…


ASCO GU 2024
Gleason 3+3 ska vi kalla de cancer eller inte?


ASCO GU 2024
Post-RP salvage radyoterapi hormonoterapi ile konbine…


ACE
ASCO GU 2024
Kognitiv påverkan av abirateron och enzalutamid?


BRCAaway
ASCO GU 2024
BRCAAway - PARP hämmare, abiraterone eller i…
Urothelial cancer - Discussions


AMBASSADOR, CHECKMATE-274
ASCO GU 2024
Advances in (neo)-adjuvant treatment in urothelial…


TROPHY-U-01
ASCO GU 2024
ADC + ICI: new data for platinum-refractory bladder…


EV-302
ASCO GU 2024
New standard of care, but still open questions!


COXEN
ASCO GU 2024
The emerging field of biomarkers in bladder cancer
Urothelial cancer - 100 sec


AMBASSADOR
ASCO GU 2024
Pembrolizumab adjuvant in bladder cancer


ASCO GU 2024
HER2 and bladder cancer


UNITE
ASCO GU 2024
EV as standard in 3rd line mUC


CheckMate 274
ASCO GU 2024
Adjuvant Nivolumab Shows Promise in Boosting Long-Term…


EV-302
ASCO GU 2024
Should we start forgetting the Galsky Criteria in…


Ambassador
ASCO GU 2024
Adjuvant therapy in urothelial carcinoma : is the…


ABACUS Ambassador EV-302
ASCO GU 2024
ASCO GU24 - Highlights in Bladder cancer


Ambassador, EV-302, ABACUS
ASCO GU 2024
Highlights in bladder cancer at ASCO GU24


Ambassador, CheckMate 274
ASCO GU 2024
Perioperative adjuvant therapy in urothelial cancer


EV-302
ASCO GU 2024
Update M1 urothelial cancer


Ambassador, CheckMate 274
ASCO GU 2024
Another success for an ICI?


AMBASSADOR, CheckMate-274
ASCO GU 2024
MIBC: adjuvant PD1 - all set?!


EV-302
ASCO GU 2024
EV + Pembro new first-line standard in localized…


ABACUS
ASCO GU 2024
Biomarker update


EV-302
ASCO GU 2024
Update on EV-302
Urothelial cancer - multilanguage


Ambassador, CheckMate 274
ASCO GU 2024
Encore un succès pour une ICI ?


EV-302
ASCO GU 2024
¿Deberíamos empezar a olvidarnos de los Criterios de…


ABACUS, Ambassador, EV-302, KEYNOTE-564, LITESPARK-005
ASCO GU 2024
νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24


EV-302
ASCO GU 2024
Novedades sobre EV-302


Ambassador
ASCO GU 2024
Tratamiento adyuvante en cancer urotelial: ¿está…


Ambassador, CheckMate 274
ASCO GU 2024
Terapia adyuvante perioperatoria en el cáncer de vejiga
Renal cell carcinoma - Discussions


Litespark-005
ASCO GU 2024
No surprise with the QoL data


KEYNOTE-564, CheckMate 914
ASCO GU 2024
Adjuvant therapy in kidney cancer: Is immunotherapy the…


CheckMate 9ER, CheckMate 214, CLEAR
ASCO GU 2024
Trial updates at ASCO GU24: Are the follow-up data…


CheckMate 67T
ASCO GU 2024
Subcutaneous vs. intravenous application: ready for…
Renal cell carcinoma - 100 sec


KEYNOTE-564
ASCO GU 2024
Perioperative treatment in renal cell carcinoma - did…


LBA359
ASCO GU 2024
Overall survival benefit - Pembro after surgery


CABATEN
ASCO GU 2024
Cabozantinib Plus Atezolizumab in Adrenocortical…


Check Mate 914, KEYNOTE-564
ASCO GU 2024
Practice changing adjuvant therapy?!


CheckMate 214
ASCO GU 2024
Durable effects of Ipi-Nivo


Keynote-564, CheckMate 914, CheckMate 67T, Litespark-005, CheckMate 214, CLEAR
ASCO GU 2024
Highlights in kidney cancer at ASCO GU24


CheckMate-67T
ASCO GU 2024
Subcutaneous Nivolumab Matches IV Formulation in Clear…


CheckMate 214
ASCO GU 2024
Long-Term Data on NIVO+IPI in aRCC


KEYNOTE-564 LITESPARK-005
ASCO GU 2024
ASCO GU24 - Highlights in renal cell carcinoma


CheckMate-9ER
ASCO GU 2024
Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…


CheckMate-9ER, CheckMate-214, Clear
ASCO GU 2024
Long-term follow-up of first-line trials


CheckMate 914
ASCO GU 2024
Long-term outcome


Litespark-005
ASCO GU 2024
Belzutifan: Updates on QoL


Litespark-005
ASCO GU 2024
Better QoL with Belzutifan


CLEAR
ASCO GU 2024
Tumorburden and outcome
Renal cell carcinoma - multilanguage


ABACUS, Ambassador, EV-302, KEYNOTE-564, LITESPARK-005
ASCO GU 2024
νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24


KEYNOTE-564
ASCO GU 2024
Tratamiento perioperatorio en cancer renal: ¿Hemos…